Developing novel medicines that modulate metabolic pathways in immune cells to treat disease


Rheos Medicines is a biopharmaceutical company developing novel medicines that modulate metabolic pathways in immune cells to treat disease. The company’s approach targets the underlying cellular metabolism of immune cells to redirect the fate and function of specific cell types to treat immune-mediated disease. By simultaneously identifying new drug targets and characterizing biomarkers of disease the company is bringing precision to the treatment of immune-mediated diseases.


Year Invested: 2018
Location: Cambridge, MA
Visit: www.rheosrx.com

Recent News

October 10, 2018
Rheos Medicines Expands Leadership Team with Appointments of Gad Soffer as Chief Operating Officer and J. Duncan Higgons to Board of Directors

September 6, 2018
Rheos Medicines Appoints Sanjay Keswani as Chief Executive Officer to Lead Company’s Pioneering Drug Development in Immunometabolism

March 22, 2018
Third Rock Ventures Launches Rheos Medicines with $60 Million in Series A Funding to Harness Immunometabolism to Develop Precision Medicines for Immune-mediated Diseases

Read More News

Associated Team Members

Abbie Celniker, Ph.D.
Partner

Cary Pfeffer, M.D.
Partner

Stephen Sherwin, M.D.
Venture Partner

Claire Mazumdar, Ph.D., M.B.A.
Senior Associate